CLINICAL SCALE EXPANSION OF HUMAN DENDRITIC CELLS
CLINICAL SCALE EXPANSION OF HUMAN DENDRITIC CELLS
批准号:
2645337
负责人:
DOUGLAS Matthew SMITH
金额:
$9.88万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-06-01 至 1998-11-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Adapted from the applicant's abstract): Dendritic cells
(DCS) are highly specialized bone marrow-derived antigen presenting
cells (APCs) which function as potent stimulating cells for T-
lymphocyte-mediated immune responses. Dendritic cell-based immunotherapy
is an emerging treatment strategy involving ex vivo expansion and
reinfusion of antigen-pulsed DCS into human patients to vaccinate
against cancer or infectious diseases. A major limitation in this
approach has been the capability to generate sufficient quantities of
functional DCS for effective patient therapy. The primary objective of
the proposed studies is to develop and implement a unique process for
ex vivo expansion, differentiation, tumor antigen-loading and harvest
of DCS in a continuously perfused clinical-scale bioreactor system. The
hypothesis that continuous single-pass medium exchange will enable
enhanced production of functional DCS at high density in Aastrom's Cell
Production System (CPS) will be tested. The Phase II program will focus
on optimization and full automation of the process in compliance with
GMP regulations. The automated system will be tested in clinical trials
to assess the safety and efficacy of dendritic cells produced in the CPS
for human carcino-embryonic antigen (CEA-specific cancer therapy. An
automated clinical scale bioreactor system would enable efficient
production of highly functional dendritic cells as a superior APC type
for cancer immunotherapy.
PROPOSED COMMERCIAL APPLICATION:
A closed, automated, GMP system for dendritic cell expansion,
differentiation, antigen-loading and harvest would be of great value for
immunotherapy of cancer and infectious diseases. The existing methods
for dendritic cell expansion involve multiple open process steps with
associated costs in equipment and labor. The development of a CPS-based
DC expansion process will enable widespread application of successful
dendritic cell-based therapies in a reliable and cost-effective fashion.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dendritic Cell Subset for Enhanced Cancer Vaccine
-
批准号:6832676
-
项目类别:
-
资助金额:$10.96万
-
财政年份:2004
-
负责人:DOUGLAS Matthew SMITH
-
依托单位:
Bioreactor for Enhanced T-cell Based Therapy of Melanoma
-
批准号:6791918
-
项目类别:
-
资助金额:$12.42万
-
财政年份:2004
-
负责人:DOUGLAS Matthew SMITH
-
依托单位:
Enhanced Tumor Antigen Priming of Dendritic Cell Vaccine
-
批准号:6644684
-
项目类别:
-
资助金额:$10.13万
-
财政年份:2003
-
负责人:DOUGLAS Matthew SMITH
-
依托单位:
EXPANSION AND GENETIC TRANSDUCTION OF EBV-SPECIFIC CTLS
-
批准号:2867484
-
项目类别:
-
资助金额:$9.98万
-
财政年份:1999
-
负责人:DOUGLAS Matthew SMITH
-
依托单位:
CLINICAL SCALE EXPANSION OF HUMAN DENDRITIC CELLS
-
批准号:6073465
-
项目类别:
-
资助金额:$33.43万
-
财政年份:1998
-
负责人:DOUGLAS Matthew SMITH
-
依托单位:
CLINICAL SCALE EXPANSION OF HUMAN DENDRITIC CELLS
-
批准号:6376770
-
项目类别:
-
资助金额:$42.15万
-
财政年份:1998
-
负责人:DOUGLAS Matthew SMITH
-
依托单位:
OPTIMIZED EXPANSION/TRANSDUCTION OF HEMATOPOIETIC CELLS
-
批准号:6177827
-
项目类别:
-
资助金额:$18.13万
-
财政年份:1997
-
负责人:DOUGLAS Matthew SMITH
-
依托单位: